Eric Dobmeier is a executive and board member with over two decades of leadership and operating experience in the biotechnology industry. He is currently a Venture Partner at Samsara BioCapital and serves on the boards of directors of Structure Therapeutics, (Nasdaq: GPCR), Janux Therapeutics (Nasdaq: JANX) and several private biotechnology companies.
Prior to Samsara, he was President and CEO of Chinook Therapeutics, a biotechnology company focused on developing precision medicines for kidney disease that was acquired by Novartis for $3.5 billion in 2023. Previously, he was President and CEO of Silverback Therapeutics, and before that held positions of increasing responsibility over more than 15 years at Seagen, including Chief Operating Officer and Chief Business Officer. During his career, he has been directly involved in raising more than $2 billion in equity capital, and led negotiation of corporate alliances with many leading biotechnology and pharmaceutical companies.
Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University.